Thyroid Diseases
Welcome,         Profile    Billing    Logout  
 62 Companies   89 Products   89 Products   76 Mechanisms of Action   2 Trials   652 News 


12345678910111213...1314»
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  THOP2: Study of Thyroid Hormones in Prematures (clinicaltrials.gov) -  Apr 24, 2019   
    P3,  N=0, Withdrawn, 
    N=500 --> 52 N=1224 --> 0 | Trial completion date: May 2021 --> May 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2016 --> May 2025
  • ||||||||||  Trial completion, Enrollment change:  Remission Induction and Sustenance in Graves' Disease 2 (clinicaltrials.gov) -  Jan 10, 2019   
    P=N/A,  N=139, Completed, 
    N=120 --> 55 Active, not recruiting --> Completed | N=250 --> 139
  • ||||||||||  irinotecan / Generic mfg.
    Trial termination, Metastases:  Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer (clinicaltrials.gov) -  Dec 6, 2018   
    P2,  N=6, Terminated, 
    Active, not recruiting --> Completed | N=250 --> 139 Completed --> Terminated; Closed due to early stopping rule
  • ||||||||||  ofranergene obadenovec (VB-111) / NanoCarrier, VBL Therap
    Trial completion, Metastases:  Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer (clinicaltrials.gov) -  Oct 23, 2018   
    P2,  N=29, Completed, 
    N=30 --> 21 | Trial completion date: Aug 2020 --> Oct 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Oct 2018; Institutional RDRC dissolved Active, not recruiting --> Completed
  • ||||||||||  thyroxine / Generic mfg.
    Phase classification, Enrollment change:  Neurocognitive and Metabolic Effects of Mild Hypothyroidism (clinicaltrials.gov) -  Aug 22, 2018   
    P4,  N=173, Completed, 
    N=30 --> 15 | Active, not recruiting --> Terminated; lack of response Phase classification: P=N/A --> P4 | N=324 --> 173
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Trial completion, Trial completion date, Trial primary completion date:  Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov) -  Aug 15, 2018   
    P2,  N=37, Completed, 
    Phase classification: P=N/A --> P4 | N=324 --> 173 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Dec 2018 --> Jan 2018
  • ||||||||||  Trial termination:  Iodine I 131 in Treating Patients With Thyroid Cancer (clinicaltrials.gov) -  Jul 18, 2018   
    P=N/A,  N=9, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Mar 2018 Completed --> Terminated; Study was terminated due to loss of funding.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  The TRUST Study - Depression Substudy (clinicaltrials.gov) -  Jun 14, 2018   
    P4,  N=426, Completed, 
    N=500 --> 62 | Recruiting --> Terminated Recruiting --> Completed | Trial completion date: Nov 2017 --> Apr 2018 | Trial primary completion date: Nov 2017 --> Apr 2018
  • ||||||||||  buparlisib (AN2025) / Novartis, Adlai Nortye
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) -  Mar 19, 2018   
    P1,  N=43, Completed, 
    Phase classification: P=N/A --> P Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Mar 2018 --> May 2017
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie
    Trial completion, Enrollment change, Trial primary completion date:  Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues (clinicaltrials.gov) -  Feb 19, 2018   
    P3,  N=10, Completed, 
    Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Mar 2018 --> May 2017 Recruiting --> Completed | N=20 --> 10 | Trial primary completion date: Dec 2015 --> May 2017
  • ||||||||||  thyroxine / Generic mfg.
    Trial completion, Phase classification, Enrollment change, Trial primary completion date:  Selenium Supplementation in Pregnancy (clinicaltrials.gov) -  Jan 30, 2018   
    P=N/A,  N=56, Completed, 
    N=45 --> 9 | Trial primary completion date: Mar 2014 --> Dec 2017 | Trial completion date: Mar 2014 --> Jun 2018 Recruiting --> Completed | Phase classification: P4 --> PN/A | N=150 --> 56 | Trial primary completion date: May 2015 --> Jun 2017
  • ||||||||||  Trial primary completion date:  Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients (clinicaltrials.gov) -  Jan 30, 2018   
    P2,  N=35, Active, not recruiting, 
    Recruiting --> Completed | Phase classification: P4 --> PN/A | N=150 --> 56 | Trial primary completion date: May 2015 --> Jun 2017 Trial primary completion date: Jan 2017 --> May 2018
  • ||||||||||  vatalanib (PTK787) / Novartis, Bayer
    Trial completion, Trial primary completion date, Combination therapy, Metastases:  Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 17, 2018   
    P1,  N=96, Completed, 
    Trial primary completion date: Jan 2017 --> May 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
  • ||||||||||  Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
    Enrollment change, Trial initiation date, Trial primary completion date:  The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (clinicaltrials.gov) -  Jan 16, 2018   
    P4,  N=0, Withdrawn, 
    Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jul 2017 N=30 --> 0 | Initiation date: Aug 2013 --> Jun 2014 | Trial primary completion date: Aug 2015 --> Dec 2016
  • ||||||||||  sorafenib / Generic mfg.
    Trial completion, Metastases:  Nexavar (clinicaltrials.gov) -  Dec 19, 2017   
    P3,  N=417, Completed, 
    Active, not recruiting --> Completed | Initiation date: May 2013 --> Sep 2013 Active, not recruiting --> Completed
  • ||||||||||  Trial completion:  Diagnosing Thyroid Cancer Using a Blood Test (clinicaltrials.gov) -  Sep 15, 2017   
    P=N/A,  N=400, Completed, 
    N=115 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: May 2016 --> May 2013 Recruiting --> Completed
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Trial completion:  Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease (clinicaltrials.gov) -  Aug 30, 2017   
    P2,  N=88, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Aug 2017 Active, not recruiting --> Completed
  • ||||||||||  Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Enrollment closed, Trial primary completion date, IO biomarker:  Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) -  Aug 22, 2017   
    P2,  N=25, Active, not recruiting, 
    Active, not recruiting --> Completed Suspended --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jul 2015
  • ||||||||||  Caprelsa (vandetanib) / Sanofi
    Trial completion, Metastases:  Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer (clinicaltrials.gov) -  Jul 17, 2017   
    P2,  N=40, Completed, 
    Suspended --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jul 2015 Active, not recruiting --> Completed